wpostServer: http://css.washingtonpost.com/wpost
Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery 04.23.2014
    On today’s show the guys talk about Amazon’s newly announced deal with HBO and what it means for the site. Plus they talk earnings from Intuitive Surgical, Yum! Brands, and more.
  • MarketFoolery: 04.22.2014
    Netflix rises on strong 1st quarter numbers and a well-executed price increase.  Valeant Pharmaceuticals makes a $45 billion bid for Allergan.  Plus, we analyze the latest results from McDonald’s and the new “Pay To Quit” program at Amazon.
  • MarketFoolery: 04.21.2014
    Hasbro shares rise on 1st-quarter profits.  LinkedIn tops the 300 million member mark.  And we dip into the Fool Mailbag to discuss the prospects for Airbnb’s potential IPO.
Capital Business
Posted at 08:59 AM ET, 05/09/2012

GlaxoSmithKline appeals directly to Human Genome Sciences shareholders in buyout dispute


Human Genome Sciences employees work on manufacturing the lupus drug, Benlysta, in Rockville, Md. (Jeffrey MacMillan/Capital Business)
British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and instead appeal directly to the Rockville firm’s shareholders to accept its $13-per-share asking price.

By issuing a tender offer this week, GSK aims to bypass the company’s board of directors, which balked at a previous acquisition offer, and instead take control of HGS by purchasing a majority of its outstanding shares.

“There is clear strategic and financial logic to this combination and HGS shareholders should have the opportunity to decide for themselves on the merits of the offer,” GSK said in a news release.

HGS released a statement on Wednesday asking its shareholders to hold off on a decision until the company has had time to review the hostile bid. Executives said they could take up to 10 business days from the time the tender offer is formally issued to respond.

In the meantime, the company said it will continue to evaluate its strategic alternatives.

GSK submitted an unsolicited bid for the company worth $2.59 billion on April 19. At that time, $13 per share marked an 81 percent premium over the stock’s closing price the previous day. Shares of the company have since been trading higher and closed at $14.62 Tuesday.

That offer was rejected, however, as HGS executives said the proposal undervalued the company’s long-term financial prospects, including the money it stands to make from sales of its flagship drug, Benlysta, which is designed to treat systemic lupus.

HGS and GSK have partnered on the development of several drugs, including Benlysta, in recent years and industry observers have long speculated that a merger is likely.

“GSK continues to believe that now is the appropriate time in the evolution of the GSK/HGS relationship for the companies to combine and that GSK is uniquely positioned to deliver on the promises of Benlysta, albiglutide and darapladib,” the statement said.

By  |  08:59 AM ET, 05/09/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company